SALT LAKE CITY - Recursion Pharmaceuticals (NASDAQ:RXRX) announced Monday that its investigational drug REC-4881 demonstrated significant polyp reduction in patients with familial adenomatous ...

Recursion’s FAP drug shows durable polyp reduction in phase 1b/2 trial ...

Greater availability of real-world data and real-world evidence is rapidly changing the landscape of drug development. At Reuters Pharma USA, Hemanth Kanakamedala, vice president of decision science ...

The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...

Python 3.11 introduced the Specializing Adaptive Interpreter. When the interpreter detects that some operations predictably involve the same types, those operations are “specialized.” The generic ...

Sept 3 (Reuters) - Nvidia-backed Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage ...

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...

(Reuters) -Nvidia-backed Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results ...

For years, drug developers that apply artificial intelligence (AI) have touted the benefits of the technology—the prospect of speedier development of new treatments at lower cost, thus reducing the ...